Lancet sub-journal: Karelli pearl single anti-scale non-scale NSCLC maximum total lifetime

For patients with advanced non-squamous non-small cell lung cancer (NSCLC) without EGFR or ALC mutations, immunotherapy in combination with chemotherapy is the most common and effective treatment.
but there is a lack of evidence in the Asian population.
December 18, the study published in the Lancet sub-journal published the clinical trial data of China Hengrui Pharmaceuticals' independent research and development of PD-1 camrelizumab in combination with permeable curvature compared with chemotherapy alone in patients with advanced non-scaly NSCLC.
random, open label, multi-center, Phase 3 clinical trial (CamelL) led by Shanghai Lung Hospital, carried out in 52 hospitals in China.
a total of 419 patients were included between 2017.5.12 and 2018.6,6, of whom 417 non-scale NSCLC patients without EGFR ALC mutation were randomly divided into two groups for treatment: carelli's single-anti-combination chemotherapy (carbaptin-pemonics) or individual chemotherapy.
end events are progress-free survival (PFS) in all patients and in patients with positive PD-L1.
of the events was the total survival of the patient and the oncology imaging assessment that was not conducted for 6-12 weeks.
-term analysis, the medium follow-up time was 11.9 months.
compared to the individual chemotherapy group, the mid-level PFS in the combined treatment group was significantly extended (11.3 vs. 8.3 months, HR=0.60), and the risk of disease progression or patient death was reduced by 40%, reaching the main focus event of the study.
PFS with two groups of patients.
When the PD-L1 tumor ratio score was further analyzed as a covariate ≥, it was found that the combined treatment group still had PFS higher than the chemotherapy group leader (HR-0.62), with 49.6% and 35.1% of patients in the two groups reaching the 12-month PFS target, respectively.
, in the patient subgroup with a PD-L1 tumor ratio score of ≥1%, the combined treatment group reduced the patient's risk of progression or death by 44% (medium PFS 15.4 months vs 9.9 months).
the mid-term analysis, a total of 143 patients died.
K-M curve analysis showed that the joint group increased the total survival of the patients in the middle (OR did not reach vs 20.9 months, HR s 0.73).
12-month total survival of the combined treatment group and the chemotherapy group was 74.9% and 67.1%, respectively.
the mixed factors, it was found that combined therapy improved patient survival by 39%.
total survival time K-M curve.
The most common treatment-related adverse events in this trial were a decrease in the number of neutral granulocytes (combined treatment group vs chemotherapy group: 38% vs 30%), a decrease in white blood cell count (20% vs 14%), anemia (19% vs 11%) and a decrease in plateplate count (17% vs 12%).
, 74 (36%) and 27 (13%) patients were reported in both groups;
the results prove that the total survival of the advanced non-scale NSCLC in the first-line treatment of Karelli's mono-anti-combination chemotherapy was 27.9 months, the researchers noted.
data is the world's longest survival benefit data in clinical studies of immunotherapy for lung cancer, successfully breaking the two-year mark.
also marks that China's lung cancer immunotherapy is enough to meet the international leading level.
, the drug was approved by China's National Drug Administration (NMPA).
: Caicun Zhou, et al., (2020). Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. The Lancet Health Medicine, DOI: MedSci Original Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Met Medical" or "Source: MedSci Original" are owned by Mets Medicine and are not authorized to reproduce by any media, website or individual, and must be reproduced with the words "Source: Met Medical".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here